Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
1.435EUR
188.24 MEUR
1.66 BEUR
278.25 M
About Exelixis, Inc.
Sector
CEO
Michael M. Morrissey
Headquarters
Alameda
Website
Founded
1994
FIGI
BBG000BL33N5
Exelixis, Inc. operates as an oncology company, which focuses on discovering, developing, and commercialization of new medicines for difficult-to-treat cancers. Its products include cabometyx, cometriq, and cotellic. The company was founded by Stelios Papadopoulos on November 15, 1994, and is headquartered in Alameda, CA.
An aggregate view of professional's ratings.
Displays a symbol's price movements over previous years to identify recurring trends.
Curated watchlists where EX9 is featured.
Frequently Asked Questions
Depending on the exchange, the stock ticker may vary. For instance, on SWB exchange Exelixis Inc. stocks are traded under the ticker EX9.
We've gathered analysts' opinions on Exelixis Inc. future price: according to them, EX9 price has a max estimate of 35.00 EUR and a min estimate of 21.18 EUR. Watch EX9 chart and read a more detailed Exelixis Inc. stock forecast: see what analysts think of Exelixis Inc. and suggest that you do with its stocks.
Yes, you can track Exelixis Inc. financials in yearly and quarterly reports right on TradingView.
Exelixis Inc. is going to release the next earnings report on Feb 11, 2025. Keep track of upcoming events with our Earnings Calendar.
EX9 earnings for the last quarter are 0.36 EUR per share, whereas the estimation was 0.30 EUR resulting in a 17.88% surprise. The estimated earnings for the next quarter are 0.35 EUR per share. See more details about Exelixis Inc. earnings.
Exelixis Inc. revenue for the last quarter amounts to 484.59 M EUR, despite the estimated figure of 440.37 M EUR. In the next quarter, revenue is expected to reach 510.83 M EUR.
EX9 net income for the last quarter is 105.96 M EUR, while the quarter before that showed 211.10 M EUR of net income which accounts for −49.81% change. Track more Exelixis Inc. financial stats to get the full picture.
No, EX9 doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Nov 5, 2024, the company has 1.31 K employees. See our rating of the largest employees — is Exelixis Inc. on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. Exelixis Inc. EBITDA is 571.19 M EUR, and current EBITDA margin is 10.74%. See more stats in Exelixis Inc. financial statements.
Like other stocks, EX9 shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Exelixis Inc. stock right from TradingView charts — choose your broker and connect to your account.